Completed NCT00013000
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Washington D.C. Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Behavioral From 18 Years to 65 Years
Countries United States
Sponsor US Department of Veterans Affairs
Condition Schizophrenia Completed NCT02220712
This study is completed in Japan. It focuses on schizophrenia.
Multiple locations, including Chugoku Region Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 64 Years
Countries Japan
Sponsor Otsuka Pharmaceutical Co., Ltd.
Condition Schizophrenia Completed NCT00505765
This study is completed in the United States. It is testing NAP for schizophrenia.
Multiple locations, including Los Angeles Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 60 Years
Countries United States
Sponsor University of California, Los Angeles
Condition Schizophrenia Completed NCT04136873
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Bentonville Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 55 Years
Countries United States
Sponsor Cerevel Therapeutics, LLC
Condition Schizophrenia Completed NCT01870999
This study is completed in the United States. It focuses on schizophrenia.
Multiple locations, including Cerritos Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 64 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Schizophrenia Completed NCT00888693
This study is completed. It is testing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 for schizophrenia.
Location not clearly listed Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 60 Years
Countries
Sponsor AbbVie
Condition Schizophrenia Completed NCT00922090
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Busan Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Observational i A study where researchers collect information without assigning a treatment. From 18 Years to 65 Years
Countries South Korea
Sponsor AstraZeneca
Condition Schizophrenia Completed NCT01959659
This study is completed in Australia, in France, in Czechia, .... It focuses on schizophrenia.
Multiple locations, including Epping Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Observational Over 18 Years
Countries Australia, France, Czechia, ...
Sponsor Hoffmann-La Roche
Condition Schizophrenia Completed NCT01606254
This study is completed in Japan. It is testing paliperidone Palmitate for schizophrenia.
In Ichikawa Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 20 Years to 65 Years
Countries Japan
Sponsor Janssen Pharmaceutical K.K.
Condition Schizophrenia Completed NCT01812642
This study is completed in Belgium, in Germany, in Russia, .... It is testing JNJ-37822681 for schizophrenia.
Multiple locations, including Antwerp Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 20 Years to 55 Years
Countries Belgium, Germany, Russia, ...
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition Schizophrenia Completed NCT02804568
This study is completed in the United States. It focuses on schizophrenia.
Multiple locations, including Little Rock Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 55 Years
Countries United States
Sponsor Alkermes, Inc.
Condition Schizophrenia Completed NCT02477020
This study is completed in the United States. It is testing TAK-063 for schizophrenia.
Multiple locations, including Springdale Why is this study shown? This study is directly about Schizophrenia.
Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor Takeda
Condition Schizophrenia